5 June 2017 - - US-based biopharmaceutical company Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) chief financial officer, Ryan Daws, will be leaving the company in early June 2017 to return to investment banking, the company said.
He will be joining Baird as Managing director in the firm's Life Sciences and biotechnology Group.
Daws will continue to consult with the company, including through the closing of the pending asset purchase agreement with Vertex Pharmaceuticals, Inc.
Daws served as CFO of Concert since January 2014.
Concert has initiated a search to appoint a new CFO.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs.
The company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems disorders.